Quarterly report pursuant to Section 13 or 15(d)

Revenue Disaggregation

v3.24.2.u1
Revenue Disaggregation
 3 Months Ended
Jun. 30, 2024
Revenue from Contract with Customer [Abstract]  
Revenue Disaggregation

 

Note 10. Revenue Disaggregation

 

The Company generates product revenues from products which are sold into the human and animal healthcare markets, and the Company generates service revenues from laboratory testing services which are provided to medical device manufacturers.

 

The following table presents the Company’s disaggregated revenues by source:

           
    Three Months Ended June 30,  
Product   2024     2023  
Human Care   $ 2,876,000     $ 2,750,000  
Animal Care     399,000       578,000  
Total Product     3,275,000       3,328,000  
Service and Royalty     116,000       99,000  
Total   $ 3,391,000     $ 3,427,000  

 

The following table shows the Company’s revenues by geographic region:

           
    Three Months Ended June 30,  
    2024     2023  
United States   $ 642,000     $ 806,000  
Europe     1,288,000       1,070,000  
Asia     477,000       862,000  
Latin America     880,000       487,000  
Rest of the World     104,000       202,000  
Total   $ 3,391,000     $ 3,427,000